Harbin Fuerji Technology Co., Ltd. (Stock Code:301371 SZ) on2023year8month1Rising successfully to the ChiNext board. Fuerjia is a company with wide market recognition and brand influence, integrating R&D, production, and sales to provide professional skin care products. The company closely follows changes in consumer demand, adopts precision marketing strategies, and leverages the new consumption momentum of domestic brands' rise and professional channel layout to gradually build its brand and product strength. Frost & SullivanFrost & SullivanFrost & Sullivan, hereinafter referred to as 'Frost & Sullivan', hereby warmly congratulates the company on its successful listing.
Harbin Furui Technology Co., Ltd. (hereinafter referred to as 'Furui') was established on2023year8month1The company was successfully listed on the stock market, with the number of shares issued being4,008.0010,000 shares, issue price per share55.68yuan.
Investment highlights
The company attaches great importance to material selection, and its star products have established a good reputation among consumers. The excellent product quality not only provides consumers with a good user experience but also further enhances customer loyalty, drives product sales, and has led to an annual increase in product sales revenue;
The company concentrates its advantageous resources to create a professional skincare production environment that meets the requirements. It conducts strict verification clinical studies on medical device products, and its quality system, workshop production control, and other procedures are strictly regulated according to pharmaceutical standards to ensure the technical content and quality level of the produced products, making the actual effects consistent with expectations;
The company adheres to controlling product quality from the source, evaluating purchased raw materials, and entrusting third-party testing institutions to inspect them to ensure the safety of product raw materials and continuously enhance consumers' trust in the brand;
In the highly competitive environment, the company has chosen to participate in competition by targeting differentiated market segments based on its own strengths. It has launched star products such as medical adhesives with high technical content and plans to layout beauty instrument products in the future. The company intends to develop other product forms besides medical dressings, focusing on the market, combining product lines with its own strengths for development, so as to enhance the company's R&D capabilities and market competitiveness.
Frost & Sullivan has long been monitoring the global and Chinese healthcare industries, publishing a large number of research reports that are widely cited in the prospectuses of leading companies listed on the ChiNext, helping clients accelerate their growth.
Overview of the Chinese Skin Care Product Market
Driven by multiple factors such as the improvement of residents' living standards, increasing emphasis on their own health and skin care, a wide variety of skin care products, and the diverse needs that can be met, Chinese residents are increasingly willing to invest more in personal care, which has promoted the rapid development of the skin care product industry.2016Year-end2020In [year], the market scale of China's skin care product industry was1,570RMB billion growth to2,769Yuan, with an annual compound growth rate of15.3%.2020Year-end2025In 2021, it is expected that the skin care product industry in China will maintain13.7%The compound annual growth rate is increasing, and it is expected to2025The market scale of the skin care product industry in China will reach5,261100 million yuan.
Data source: Analysis by Frost & Sullivan
Skin care products can be divided into basic skincare products and professional skin care products based on concept and positioning. The market size of basic skincare products and professional skin care products is divided by2016year1,478yuan92RMB billion growth to2020year2,504yuan265Yuan, with an average annual compound growth rate of14.1%and30.3%are expected2025In [year], the market scale of basic skincare products and professional skin care products will reach4,495yuan767100 million yuan.
Data source: Analysis by Frost & Sullivan
Overview of the Professional Skin Care Product Market in China
Professional skin care products can be divided into functional skincare products and medical device dressings. The market size of functional skincare products and medical device dressings is divided by2016year89.7yuan2.3RMB billion growth to2020year223.4yuan41.8Yuan, with an average annual compound growth rate of25.6%and105.7%are expected2025In [year], the market scale of functional skincare products and medical device dressings will reach565.5yuan201.4100 million yuan.
Data source: Analysis by Frost & Sullivan
Overview of the Professional Skin Care Product Market in Different Forms in China
The product forms of professional skin care products are generally divided into two major categories: patch-based and non-patch-based. Patch-based professional skin care products mainly use materials such as sheet membranes to apply essence/Products with the active ingredient applied to the skin; non-patch professional skin care products consist of essence, sub-surface liquid, water, spray, lotion, etc., which apply the essence/The composition of products that are applied directly to the skin. Patch and non-patch types are referred to as 'dressing patches' and other types in medical device dressings, and as 'patches and films' and other categories in functional skincare products.
The market scale of professional skin care products for patch and non-patch applications is2016year19.3yuan72.7RMB billion growth to2020year66.3yuan198.9Yuan, with an average annual compound growth rate of36.1%and28.6%are expected2025In [Year], the market scale of professional skin care products for patch and non-patch applications will reach230.1yuan536.8100 million yuan.
Data source: Analysis by Frost & Sullivan
Overview of the Market Development of Skin Care Products for SMT-related Specialties in China
The market scale of skin care products for patch applications has been growing at a faster rate than the overall skin care product market, indicating great potential for development. The market scale of skin care products for patch applications in China is2016year19.3RMB billion growth to2020year66.3Yuan, with an average annual compound growth rate of36.1%, faster than the overall skin care product industry during the same period. In the future, the standardization of the professional patch-based skin care product industry in China and residents' awareness of maintenance will further improve, leading to an expanding consumer base. The domestic professional patch-based skin care product industry will also grow steadily, with an estimated market scale of2025Year-on-year growth to230.1Yuan, with an average annual compound growth rate of28.3%.
Data source: Analysis by Frost & Sullivan
In the fields of medical aesthetics and professional skincare products, Frost & Sullivan has served companies such as Huaxi Biotechnology Group Co., Ltd., JuZi Bio-Tech Co., Ltd., Meiliyuan, Porelia, Shisehatang, L'Oréal, and Morita.
View the full prospectus of Fierji
Frost & Sullivan integrates the globe.62years of consulting experience,25Frost & Sullivan wholeheartedly serves the booming Chinese market, with a global perspective to help clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Among them, successful listing cases include: LaiKai Medicine 2105.HK), Kedex Group2487.HK), Lvz Bio2480.HK), Meis Health 2415.HK), Yaohua MedicinePHECR), Zhongjin Medical （NASDAQ:ZJYL), Yisheng Biology NASDAQ:YS ), Beautiful Countryside 2373.HK), Kangfeng Biology6922.HK), Bona Biotechnology6955.HK), Ideasight1244.HK), Meihao Medical (1947.HK), Gaoshi Medical (2407.HK), Lepu Xintai2291.HK), Genstar Biotech9877.HK), HealthyuanJCARE.SW), Leepu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbaimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Scientific & Pharmaceutical2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. In terms of the number of submissions, Frost & Sullivan's healthcare team in Hong Kong is involved inIPO listingMaintain an absolute leading position,2018till2022Year after year, it has always ranked first in market share.
since2019year7Since the first batch of companies on the Sci-tech Innovation Board were listed, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies in the industry, including: Guangge Technology688450.SH), Hybrid Integration688249.SH), Wuxi Rilian688531.SH), Maolai Optics688502.SH), Kangwe Century688426.SH), coastal protein688137.SH), Novartis HealthCare (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Medical Group Holdings (688197.SH), and Yuanbiotechnology (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.
Recommended Reading
Frost & Sullivan assisted Keddy Group in successfully going public in Hong Kong(2487.HK)
Frost & Sullivan assisted MesHealth in successfully listing on the Hong Kong Stock Exchange(2415.HK)
Frost & Sullivan assisted Zhongjin Medical in successfully going public in the US(NASDAQ: ZJYL)
Frost & Sullivan assisted Yisheng Biology in successfully going public in the US(NASDAQ:YS)
Frost & Sullivan assists Meiliyuan in successfully going public in Hong Kong(2373.HK)
Frost & Sullivan assisted IdeaCube in successfully going public in Hong Kong(1244.HK)
Frost & Sullivan assisted Meihao Medical in successfully going public in Hong Kong(1947.HK)
Frost & Sullivan assisted GAV Healthcare in successfully going public in Hong Kong(2407.HK)
Frost & Sullivan assisted Genius HealthTech in successfully going public in Hong Kong(9877.HK)
Frost & Sullivan assists Health Yuan in successful issuanceGDRAnd is listed on the SSE(JCARE.SW)
Frost & Sullivan assisted Dingdang Health in successfully going public in Hong Kong(9886.HK)
Frost & Sullivan assisted Zhiyun Health in successfully going public in Hong Kong(9955.HK)
Frost & Sullivan assisted MeinGene in successfully listing on the Hong Kong Stock Exchange(6667.HK)
Frost & Sullivan assistancePreneticsSuccessfully listed in the US(NASDAQ:PRE)
Frost & Sullivan assisted YunKang Group in successfully going public in Hong Kong(2325.HK)
Frost & Sullivan helps Clear Medical successfully go public in Hong Kong(1406.HK)
Frost & Sullivan assisted Baisin'an in successfully going public in Hong Kong(2185.HK)
Frost & Sullivan assisted Kaleido in successfully listing on the Hong Kong Stock Exchange(6821.HK)
Frost & Sullivan assisted Hokkaido Konka in successfully going public in Hong Kong(1228.HK)
Frost & Sullivan assisted Yingpeng Technology in successfully going public in Hong Kong(2251.HK)
Frost & Sullivan assisted Yuhuan in successfully listing on the Hong Kong Stock Exchange(2256.HK)
Frost & Sullivan assisted Kunbo Medical in successfully going public in Hong Kong(2216.HK)
Frost & Sullivan assisted Xianruida in successfully going public in Hong Kong(6669.HK)
Frost & Sullivan assisted Kangsheng Global in successfully going public in Hong Kong(9960.HK)
Frost & Sullivan assisted ConocoAL on its successful listing in Hong Kong(2162.HK)
Frost & Sullivan assisted Chaoyu Eye Hospital in successfully going public in Hong Kong(2219.HK)
Frost & Sullivan assisted Nature Pharma in successfully going public in the US(NASDAQ:UPC)
Frost & Sullivan assisted Jianbimiao Miao in successfully going public in Hong Kong(2161.HK)
Frost & Sullivan assisted RuiLi Medical Beauty in successfully going public in Hong Kong(2135.HK)
Frost & Sullivan assisted GC Pharma in successfully listing on the Hong Kong Stock Exchange(1167.HK)
Frost & Sullivan assisted Jiahé Biotech in successfully going public in Hong Kong(6998.HK)
Frost & Sullivan assisted Hype Pharma in successfully going public in Hong Kong(9989.HK)
Frost & Sullivan assisted Peijia Medical in successfully going public in Hong Kong(9996.HK)
Frost & Sullivan assisted Kangfang Biotech in successfully going public in Hong Kong(9926.HK)
Frost & Sullivan assisted Tianjing Biology in successfully going public in the US(NASDAQ: IMAB)
Frost & Sullivan assisted Concha Chemicals in successfully going public in Hong Kong(3759.HK)
Frost & Sullivan assisted ViaBio in successfully going public in Hong Kong(1873.HK)
Frost & Sullivan assisted WuXi AppTec in successfully going public in Hong Kong(2359.HK)
Frost & Sullivan assisted BeiGene in successfully listing on the Hong Kong Stock Exchange(6160.HK)
Frost & Sullivan assisted Hualong China Medicine in successfully going public in the US(NASDAQ:HCM)
Frost & Sullivan assisted KingsRice Biotechnology in successfully going public in Hong Kong(1548.HK)
*The above order is not sequential and is arranged in reverse chronological order by listing time.
2023Frost & Sullivan New Investment Conference
PHDI 2023
